Overview

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Status:
Active, not recruiting

Trial end date:
2023-01-25

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Osimertinib